1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
  5. > Global Osteoporosis Partnering 2010-2015

Global Osteoporosis Partnering 2010-2015

  • July 2015
  • -
  • Currentpartnering
  • -
  • 100 pages

The report will be delivered in PDF format within 3 working days of receipt of order. If print or CD-Rom version purchased, the report will be sent by courier using express service.

The Osteoporosis Partnering 2010-2015 report provides understanding and access to the osteoporosis partnering deals and agreements entered into by the worlds leading healthcare companies.

•Trends in osteoporosis partnering deals
•Top osteoporosis deals by value
•Deals listed by company A-Z, industry sector, stage of development, technology type

The Osteoporosis Partnering 2010-2015 provides understanding and access to the osteoporosis partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides an analysis of osteoporosis partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors asthma technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This data driven report contains over 80 links to online copies of actual osteoporosis deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of osteoporosis partnering trends.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in osteoporosis partnering since 2010, including a summary of deals by industry sector, stage of development, deal type, and technology type. Numerous tables provide outline financial trends.

Chapter 3 provides an overview of the leading osteoporosis deals since 2010. Deals are listed by headline value, signed by bigpharma, most active bigpharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive directory of osteoporosis partnering deals signed and announced since 2010. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of osteoporosis technologies and products.

Report scope

Osteoporosis Partnering 2010-2015 is intended to provide the reader with an in-depth understanding and access to osteoporosis trends and structure of deals entered into by leading companies worldwide.

This data driven report includes:

•Trends in osteoporosis dealmaking in the biopharma industry since 2010
•Access to summary headline, upfront, milestone and royalty data
•The leading osteoporosis deals by value since 2010

In Osteoporosis Partnering 2010-2015, the available deals are listed by:

•Headline value
•Upfront payment value
•Royalty rate value
•Company A-Z
•Industry sector
•Stage of development at signing
•Deal component type
•Technology type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Osteoporosis Partnering 2010-2015 provides the reader with the following key benefits:


•In-depth understanding of osteoporosis deal trends since 2010
•Access to summary headline, upfront, milestone and royalty data
•Comprehensive access to over 80 actual osteoporosis deals entered into by the world’s biopharma companies since 2010
•Insight into key deal terms included in contracts, where disclosed
•Understand the key deal terms companies have agreed in deals
•Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Table Of Contents

Global Osteoporosis Partnering 2010-2015
Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in osteoporosis partnering

2.1. Introduction
2.2. Osteoporosis partnering over the years
2.3. Big pharma osteoporosis dealmaking activity
2.4. Big biotech osteoporosis dealmaking activity
2.5. Most active osteoporosis dealmakers
2.6. Osteoporosis partnering by deal type
2.7. Osteoporosis partnering industry sector
2.8. Osteoporosis partnering by stage of development
2.9. Osteoporosis partnering by technology type
2.10. Disclosed financial deal terms for osteoporosis
2.10.1 Osteoporosis headline values
2.10.2 Osteoporosis upfront payments
2.10.3 Osteoporosis milestone payments
2.10.4 Osteoporosis royalty rates

Chapter 3 - Leading osteoporosis deals

3.1. Introduction
3.2. Top osteoporosis deals by value

Chapter 4 - Dealmaking directory

4.1. Introduction
4.2. Company A-Z
4.3. By deal type
4.4. By industry sector
4.5. By stage of development
4.6. By technology type

Chapter 5 - Partnering resource center

5.1. Online partnering
5.2. Partnering events
5.3. Further reading on dealmaking

Appendices

Appendix 1 - Deal type definitions

About Wildwood Ventures

Current Partnering
Current Agreements
Recent report titles from Current Partnering
Order Form - Reports
Order Form - Subscription Access Products

Table of figures

Figure 1: Osteoporosis partnering since 2010
Figure 2: Big pharma - top 50 - osteoporosis deals 2010 to 2015
Figure 3: Big pharma osteoporosis deal frequency - 2010 to 2015
Figure 4: Big biotech - top 50 - osteoporosis deals 2010 to 2015
Figure 5: Big biotech osteoporosis deal frequency - 2010 to 2015
Figure 6: Osteoporosis dealmaking activity- 2010 to 2015
Figure 7: Osteoporosis partnering by deal type since 2010
Figure 8: Osteoporosis partnering by industry sector since 2010
Figure 9: Osteoporosis partnering by stage of development since 2010
Figure 10: Osteoporosis partnering by technology type since 2010
Figure 11: Osteoporosis deals with a headline value
Figure 12: Osteoporosis deals with upfront payment values
Figure 13: Osteoporosis deals with milestone payments
Figure 14: Osteoporosis deals with royalty rates, %
Figure 15: Top osteoporosis deals by value since 2010
Figure 16: Online partnering resources
Figure 17: Forthcoming partnering events
Figure 18: Deal type definitions

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Systemic Lupus Erythematosus Market: By Therapies (Antimalarial Drugs, Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids Cytotoxic & Immunosuppressive Drugs, Biologics, Small Molecules) & By Region (Asia-Pacific, Others)-Forecast (2016-2021)

Systemic Lupus Erythematosus Market: By Therapies (Antimalarial Drugs, Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids Cytotoxic & Immunosuppressive Drugs, Biologics, Small Molecules) & By Region (Asia-Pacific, Others)-Forecast (2016-2021)

  • $ 5250
  • Industry report
  • September 2016
  • by Industry ARC

Systemic lupus erythematosus, also commonly known as lupus, is an autoimmune disease which results in inflammation of tissues in the body with common symptoms like fever, fatigue, skin rashes, malaise, ...

Epiomic Epidemiology Series: Osteoarthritis Forecast in 9 Major Markets 2016-2026

Epiomic Epidemiology Series: Osteoarthritis Forecast in 9 Major Markets 2016-2026

  • $ 5112
  • Industry report
  • October 2016
  • by Black Swan Analysis Ltd132

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Osteoarthritis in 9 Major Markets Osteoarthritis (OA), also known as degenerative joint disease / degenerative arthritis, is an inflammation ...

Global Osteoporosis Drugs Market Size, Share, Development, Growth and Demand Forecast to 2022- Industry Insights by Drug Class

Global Osteoporosis Drugs Market Size, Share, Development, Growth and Demand Forecast to 2022- Industry Insights by Drug Class

  • $ 5100
  • Industry report
  • November 2016
  • by P&S Market Research

The global osteoporosis drugs market was worth $8,835.4 million in 2015 and it is expected to grow at a CAGR of 3.8% during 2016-2022. Among the various drug classes, the rank ligand inhibitors segment ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.